Treatment Patterns and Survival Outcomes of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Survival at a Safety-Net Hospital

被引：0
|
作者：
Sabloak, Krishti [1 ]
Derton, Abigail [2 ]
Teigen, Kari [2 ]
Gonzales, Mario [3 ]
Ghabach, Bassam [3 ]
Narra, Kalyani [3 ]
机构：
[1] UNT Hlth Sci Ctr, Ft Worth, TX USA
[2] JPS Hlth Network, Off Clin Res, Ft Worth, TX USA
[3] JPS Hlth Network, JPS Oncol & Infus Ctr, Ft Worth, TX USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP01.40
引用
收藏
页码：E22 / E22
页数：1
相关论文
共 50 条
  • [21] Immune checkpoint inhibitors in non-small cell lung cancer
    Eberhardt, Wilfried Ernst Erich
    ONKOLOGE, 2017, 23 (10): : 838 - 844
  • [22] Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Herzberg, Benjamin
    Campo, Meghan J.
    Gainor, Justin F.
    ONCOLOGIST, 2017, 22 (01): : 81 - 88
  • [23] TREATMENT PATTERNS, SURVIVAL, AND MEDICARE SPENDING FOR ADVANCED LUNG CANCER IN THE ERA OF IMMUNE CHECKPOINT INHIBITORS
    Youn, B.
    Wilson, I. B.
    Mor, V
    Trikalinos, N.
    Dahabreh, I. J.
    VALUE IN HEALTH, 2020, 23 : S61 - S61
  • [24] Cost-Effectiveness of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
    Kuhlmann, A.
    Schmidt, T.
    Treskova, M.
    Golpon, H.
    Welte, T.
    Von der Schulenburg, J. -Graf
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2302 - S2303
  • [25] The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
    Ren, Sijia
    Xiong, Xinxin
    You, Hua
    Shen, Jianfei
    Zhou, Penghui
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [26] Efficacy and Prognostic Factors of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer
    Hu, Yu-xiong
    Guo, Li-jing
    Lin, Meng-qing
    Lin, Qing-yu
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2023, 46 (04): : 161 - 166
  • [27] Safety of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients with Interstitial Lung Abnormalities or Disease
    Nakazawa, S.
    Kato, M.
    Soma, S.
    Namba, H.
    Arai, Y.
    Motomura, H.
    Ochi, Y.
    Kurokawa, K.
    Sumiyoshi, I.
    Watanabe, J.
    Ihara, H.
    Asao, T.
    Shimada, N.
    Togo, S.
    Sasaki, S.
    Takahashi, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [28] Two centres experience of lung cancer resection in patients with advanced non-small cell lung cancer upon treatment with immune checkpoint inhibitors: safety and clinical outcomes
    Beattie, Rory
    Furrer, Katarzyna
    Dolan, Daniel P.
    Curioni-Fontecedro, Alessandra
    Lee, Daniel N.
    Frauenfelder, Thomas
    Hoeller, Sylvia
    Weder, Walter
    Bueno, Raphael
    Opitz, Isabelle
    Swanson, Scott
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2021, 60 (06) : 1297 - 1305
  • [29] Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors
    Hendriks, Lizza E. L.
    Bootsma, Gerben
    Mourlanette, Jean
    Henon, Clemence
    Mezquita, Laura
    Ferrara, Roberto
    Audigier-Valette, Clarisse
    Mazieres, Julien
    Lefebvre, Corentin
    Duchemann, Boris
    Cousin, Sophie
    le Pechoux, Cecile
    Botticella, Angela
    De Ruysscher, Dirk
    Dingemans, Anne-Marie C.
    Besse, Benjamin
    EUROPEAN JOURNAL OF CANCER, 2019, 116 : 182 - 189
  • [30] Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer
    Kuo, Chih-Hsi Scott
    Wang, Chin-Chou
    Huang, Yu-Chen
    Pavlidis, Stelios
    Liu, Chien-Ying
    Ko, How-Wen
    Chung, Fu-Tsai
    Lin, Tin-Yu
    Wang, Chih-Liang
    Guo, Yi-Ke
    Yang, Cheng-Ta
    THORACIC CANCER, 2019, 10 (05) : 1158 - 1166
12345